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ABSTRACT
DIABETES MELLITUS IS ASSOCIATED WITH INCREASED PREVALENCE OF LATENT
TUBERCULOSIS INFECTION: FINDINGS FROM THE NATIONAL HEALTH AND
NUTRITION EXAMINATION SURVEY, 2011-2012
By

MARISSA MARGARET BARRON

APRIL 14, 2017

Background: Type 2 diabetes mellitus is associated with threefold higher risks of active
tuberculosis (TB) and an estimated 15% of the 10.4 million annual incident TB cases are
attributable to diabetes. While the relationship between diabetes and TB disease is wellestablished, little is known about the association between diabetes and latent TB infection
(LTBI).
Methods: We performed a cross-sectional analysis of data from the 2011-2012 cycle of the
National Health and Nutrition Examination Survey. Participants aged 20 years were eligible for
this analysis. Diabetes status was defined by glycated hemoglobin (HbA1c) as no diabetes
(5.6%), prediabetes (5.7-6.4%), and diabetes (6.5%); participants were defined as having
diabetes if they self-reported a diagnosis, regardless of HbA1c. LTBI was defined by interferon
gamma release assay (IGRA) as positive, negative, or indeterminate. We used logistic regression
to estimate the adjusted odds ratio and 95% confidence interval of LTBI comparing participants
with diabetes and prediabetes to those with no diabetes.
Results: Overall the prevalence of diabetes was 11.4% (95%CI 9.8-13.0%) and 22.1% (95%CI
20.5-23.8%) had prediabetes. The prevalence of LTBI was 5.9% (95%CI 4.9-7.0%). After
adjusting for cofounding factors, the odds of prevalent LTBI was greater among adults with
diabetes (aOR 1.91, 95%CI 1.16-3.16) compared to those without diabetes.
Conclusion: Diabetes is associated with LTBI among adults in the US, even after adjusting for
confounding factors. Given diabetes increases the risk of active TB, patients with co-prevalent
diabetes and LTBI may be targeted for LTBI treatment.
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CHAPTER I
INTRODUCTION
1.1

Background
Tuberculosis (TB) is an infectious disease that is spread by the causative agent
Mycobacterium tuberculosis (MTB). TB generally affects the lungs (known as
pulmonary TB), but may also spread to other areas of the human host (known as
extrapulmonary TB)[1]. The majority of individuals who become infected with MTB do
not develop infectious, symptomatic TB (also known as active TB); instead, their
immune systems are able to contain the MTB infection, which leads to the development
of latent tuberculosis (LTBI)[2, 3] Individuals with LTBI are not symptomatic or
infectious so long as their immune system contains the MTB infection.
In 2015, an estimated 10.4 million new cases of TB occurred worldwide, and
there were 1.4 million deaths attributed to TB[1]. In addition, an estimated one-third of
the world population has LTBI[2, 4]. In the general population, the proportion of persons
with LTBI that develop TB is low, but the risk of reactivation of LTBI to TB is increased
by comorbidities that affect immune responses[2, 5]. Reactivation of LTBI to TB only
occurs in about 10% of all infected individuals[2], but the risk of progression to TB
among patients with diabetes mellitus (DM) is approximately 3 times the risk of the
general population[6-10]. Although individuals with LTBI are not infectious, they are a
reservoir for TB in their communities. According to a review article by Getahun et al.,
modeling has shown that if a mere 8% of individuals with LTBI were “permanently
protected” annually, the incidence of TB worldwide in 2050 would be 14 times as low as
in 2013
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The association between TB and DM has been known about for centuries[11].
Studies involving TB patients have shown that previously diagnosed DM is one of the
most commonly occurring co-morbidities[6]. Of concern, the global prevalence of DM is
increasing rapidly, and the largest increases in DM prevalence will occur in settings
where TB burdens are greatest[11-13]. An estimated 95% of TB cases occur in low- and
middle-income countries, and approximately 70% of individuals with DM reside in these
same countries[12]. In 2014, an estimated 415 million adults had type 2 DM and by 2040
the prevalence is expected to reach 642 million adults worldwide[14]. Given the rapid
rise in global DM prevalence and the increased risk of TB in this population, an estimated
15% of all TB cases are currently attributed to DM[7, 15].
Observational studies have shown that DM increases the risk of TB. A 2012
cohort study conducted by Baker et al. found that individuals with type 2 DM (whether
treated or not) had a significantly higher risk of TB than individuals without type 2 DM
(adjusted hazard ratio, 2.09 [95% confidence interval, 1.10-3.95])[4]. Baker et al. also
found the risk of TB to be correlated with the amount of type 2 DM-associated
complications, with individuals with ≥2 type 2 DM complications having more than 3
times the risk of TB than individuals without type 2 DM (odds ratio, 3.45 [95%
confidence interval, 1.59-7.50])[4]. A meta-analysis conducted by Jeon et al. of 13
observational studies found a pooled risk ratio of 3.1 (95% confidence interval, 2.3-4.3)
for active TB comparing individuals with type 2 DM to individuals without type 2
DM[16].
Our study involved the use of data from the 2011-2012 cycle of the National
Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of DM
2

and LTBI among the civilian, non-institutionalized United States population. NHANES
has been conducted in the United States since the early 1960s and focuses on various
health issues and populations each cycle. Each year, NHANES retrieves data on
approximately 5,000 individuals meant to be a nationally representative sample.
Questionnaires, physical examinations, and laboratory measurements are used together to
obtain information on risk factors for various diseases and the prevalence of certain
diseases in the United States[17].
1.2 Gap and Purpose of Study
Results from recent studies using data from NHANES suggest an association
between LTBI and DM[18]. A 2016 cross-sectional study conducted by Hensel et al. also
found an association between LTBI and DM, with 43.4% and 39.1% of QFT-positive
(QuantiFERON-TB test) individuals having DM and pre-DM, respectively, compared to
25.9% of QFT-positive individuals not having DM or pre-DM[19]. Although studies
have shown an association between LTBI and DM, the association has not been further
investigated using NHANES data. Using data from the 2011-2012 cycle of NHANES, we
hypothesized that DM and pre-DM are associated with LTBI.
The objectives of this study are to:
1. Investigate participant characteristics associated with DM and LTBI
2. Determine the association of DM and pre-DM with LTBI
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CHAPTER II
REVIEW OF THE LITERATURE
2.1

Latent Tuberculosis Infection
Approximately one-third of the global population is estimated to have latent
tuberculosis infection (LTBI)[2, 3]. There were an estimated 10.4 million new cases of
TB globally and 1.4 million deaths attributed to TB in 2015[1]. Though the majority of
individuals infected with Mycobacterium tuberculosis (MTB) never progress to
symptomatic, infectious active tuberculosis (TB), these individuals with LTBI serve as a
reservoir for TB in their communities[3].
For individuals who become infected with MTB, progression to active TB only
occurs in approximately 5-10% of those infected[9]. MTB will be contained by the
immune system for the majority of those infected, and these individuals will develop
asymptomatic, non-infectious LTBI[2, 3]. The immune response to MTB begins when
the bacteria come into contact with alveolar macrophages of the lungs. In response, these
macrophages upregulate production of pro-inflammatory cytokines to signal the presence
of an infection[2]. As a result, cells such as T lymphocytes, B cells, fibroblasts, and
dendritic cells are recruited to the site of infection, which in the case of LTBI leads to the
formation of a granuloma containing the bacteria. Bacteria that survive granuloma
formation become a reservoir of latent infection[2].
Studies have shown that the levels of certain cellular immune signals may
function in the maintenance of the dormancy of LTBI. Pro-inflammatory cytokines TNFα and IFN-γ are known to be vital in maintaining the dormancy of LTBI by keeping MTB
4

contained in granulomas[2, 20, 21]. In a 2015 cross-sectional study in India involving 39
recently diagnosed active TB patients and 35 household contacts with LTBI as confirmed
by positive QuantiFERON®-TB Gold In-Tube Test (QFT-GIT) and negative chest X-ray
and smear microscopy, Pathakumari et al. reported that, following stimulation with two
MTB antigens, Rv2204c and Rv0753c, higher levels of IFN-γ were seen in whole blood
samples of those with LTBI compared to those with active TB[22]. Other studies have
also reported increased levels of TNF-α and IFN-γ in patients with LTBI compared to
patients with active TB[21, 23, 24]. Elevated levels of antimicrobial peptides (AMPs),
such as human β-defensin-2 (HBD-2), have been observed in patients infected with
LTBI[25-27]. β-defensins may play an important role in maintaining the dormancy of
LTBI, as they are able to inactivate one of the crucial proteins involved in the
proliferation of bacteria, ftsZ factor[25].
In a cross-sectional analysis of data from the 2011-2012 cycle of the National
Health and Nutrition Examination Survey (NHANES), Mancuso et al. determined the
prevalence of LTBI among the civilian, non-institutionalized population to be
approximately 4.4% by positive tuberculin skin test (TST) results and approximately
4.8% by positive QFT-GIT[28]. Mancuso et al. reported that QFT-GIT test results had a
higher specificity, especially among individuals who had received the Bacillus CalmetteGuérin (BCG) vaccine[28]. QFT-GIT may be a more reliable test for LTBI, as false
positives using the TST may occur due to cross-reactive antigens in the purified protein
derivative (PPD) also being present in non-pathogenic mycobacteria[29].
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2.2

Diabetes Mellitus
Approximately 415 million adults were living with type 2 diabetes mellitus in
2014, and the prevalence of type 2 diabetes is projected to increase to 642 million adults
worldwide by 2040[14]. Although type 1 diabetes is also a major issue, type 2 diabetes
currently comprises approximately 90% of the cases of diabetes worldwide[8]. Among
the many known risk factors for developing diabetes, obesity is known to predispose an
individual to diabetes[30-32]. The main mechanism by which obesity predisposes an
individual to developing diabetes is the elevated levels of pro-inflammatory cytokines,
such as TNF-α, seen in adipose tissue of obese individuals[30-32]. The elevated levels of
pro-inflammatory cytokines such as IL-1β, C-reactive protein (CRP), IL-6, IL-8, and
MCP-1 have been shown to precede the development of diabetes[30, 31, 33]. Elevated
levels of pro-inflammatory cytokines such as TNF-α increase the risk of developing
insulin resistance and beta cell dysfunction, key features of diabetes[30, 33].
Diabetes is associated with a chronic, low-grade inflammation that is marked by
increased levels of pro-inflammatory cytokines that reflect activation of innate
immunity[33]. In a 2015 study involving 14,876 men and women from the Gutenberg
Health Study cohort, researchers found elevated plasma levels of CRP in patients with
diabetes and pre-diabetes compared to patients without diabetes[31]. CRP is known to be
a marker of inflammation that increases in response to increased inflammation and may
be associated with insulin resistance syndrome[34]. Other studies have also demonstrated
diabetes to be associated with elevated levels of several key pro-inflammatory cytokines,
such as CRP, IFN-γ, TNF-α, IL-1β, IL-6, and IL-17[31, 34-44].
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2.3

Co-Occurring Diabetes and Tuberculosis
Despite reactivation of LTBI to active TB only occurring in approximately 10%
of individuals infected with MTB[2], certain comorbidities, such as human
immunodeficiency virus (HIV)[3, 5, 9] and diabetes[3, 6, 8], have been shown to
significantly increase the risk of LTBI reactivation to active TB. The risk of reactivation
to active TB for patients with co-occurring HIV and LTBI may exceed 10% per year,
while the average risk of reactivation to active TB for those with LTBI only is between
10% and 20% for their entire lifetime[5]. In a review article by Restrepo et al., the risk of
developing active TB in those with co-occurring LTBI and HIV is estimated to be more
than 50 times the risk in those without co-occurring HIV[9]. Among adults with HIV in
under-developed countries, the most common cause of death is TB[5]. In addition to HIV
and diabetes, there are many other factors that may impact an individual’s risk of
reactivation LTBI to active TB, including being homeless, being from a country with a
high burden of TB, and being of very young or very old age[3].
Risk of reactivation of LTBI to active TB among individuals with co-occurring
diabetes has been found to be approximately three-times the risk of reactivation among
individuals without diabetes[6-8]. With diabetes causing such a significant impact on the
risk of reactivation to active TB, an estimated 15% of all TB cases are currently
attributable to diabetes[7, 15]. The proportion of TB cases attributable to diabetes may
increase in the future[45], as the prevalence of diabetes is projected to increase to 552
million individuals worldwide by 2030, and the majority of this increase will likely occur
in low- and middle-income countries with high TB burdens[11, 12]. Currently,
approximately 95% of patients with TB live in developing, low- and middle-income
7

countries, such as in Southeast Asia, and approximately 70% of patients with diabetes
reside in those same countries[12].
Co-occurring diabetes and LTBI has been shown to have an impact on both the
innate and adaptive immune system. It is due to these immunologic effects that having
diabetes increases the risk of developing active TB[6, 19]. While not as much is known
regarding immunologic dysfunction during co-occurring diabetes and LTBI, there are a
few notable studies that have analyzed biomarkers present in individuals with both
illnesses. In a 2014 case-control study of 90 patients with LTBI (30 with co-occurring
diabetes, 30 with co-occurring pre-diabetes, 30 without diabetes), as determined by
positive QFT-GIT and normal chest radiograph, and 60 uninfected controls (30 with cooccurring diabetes and 30 without diabetes), Kumar et al. measured the circulating levels
of several cytokines. The study found decreased circulating levels of the proinflammatory cytokines IFN-γ, TNF-α, IL-1β, IL-2, IL-17, and IL-18 in subjects with cooccurring LTBI and diabetes compared to subjects with LTBI only[46]. Proinflammatory cytokines are known to be vital in the immune response against
mycobacterial infections, so decreased levels of these pro-inflammatory cytokines in
individuals with co-occurring diabetes and LTBI may increase the risk of reactivation to
active TB[46].
AMPs may also be related to immune dysfunction seen in co-occurring diabetes
and LTBI. In a 2011 cross-sectional study of 30 subjects with diabetes (10 uninfected, 10
with co-occurring LTBI, 10 with co-occurring active TB) and 30 subjects without
diabetes (10 uninfected, 10 with co-occurring LTBI, 10 with co-occurring active TB),
Gonzalez-Curiel et al. measured the gene expression of AMPs in peripheral blood
8

samples of all subjects. The study found decreased levels of gene expression for AMPs in
subjects with co-occurring diabetes and LTBI compared to subjects with LTBI only[47].
Since AMPs are known to function in the killing of engulfed or invasive bacteria[47], a
decreased level of AMPs may put individuals with co-occurring diabetes and LTBI at a
higher risk of reactivation to active TB.
Interestingly, some studies have suggested that the severity of diabetes, either by
amount of complications or by poor glycemic control, increases the risk of TB. Studies
have shown a relationship between HbA1c and blood glucose levels and the immune
response to TB[9]. In a 2012 prospective cohort study conducted by Baker et al., a
patient’s risk of TB was found to increase as the number of diabetes-related
complications increased, with a three-fold risk of TB being seen among patients with two
or more complications (OR 3.45; 95%CI 1.59-7.50)[4]. In a cohort study of 123,546
individuals who participated in a community-based health screening service in northern
Taiwan from 2005 to 2008, Lee et al. measured glycemic control using fasting plasma
glucose (FPG) and determined occurrence of TB during a follow-up period up until
December 2012. Researchers found that patients with diabetes who had poor glycemic
control (categorized by a FPG>130mg/dL) had a significantly higher hazard of TB (aHR
2.21; 95%CI 1.63-2.99) compared to patients without diabetes; however, the hazard of
TB among patients with diabetes with good glycemic control (categorized by a
FPG≤130mg/dL) was similar to the hazard of TB among patients without diabetes (aHR
0.69; 95%CI 0.35-1.36). Lee et al. also conducted a linear-dose response analysis to
determine if the hazard of TB increased with an increase in FPG and found the hazard of
TB to slightly increase with increased FPG (aHR 1.06 per 10mg/dL increase in FPG;
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95%CI 1.03-1.08)[48]. Other studies have also found higher HbA1c levels to be
associated with a higher risk of developing TB[13, 49, 50].
In addition to increasing the risk of reactivation of LTBI to active TB, cooccurring diabetes also increases the likeliness of poor TB treatment outcomes, including
treatment failure, relapse, and even death[6, 10, 11]. Patients with both diabetes and
active TB generally present with symptoms consistent with more severe clinical
manifestations, including higher smear grade and more lung cavities[51]. In a
retrospective cohort study conducted among TB cases in Georgia, Magee et al. found
patients with co-occurring diabetes and TB to be more likely to have cavitary lung
disease at the time of TB diagnosis (51%) compared to both patients with co-occurring
HIV and TB and patients with only TB – 19.9% and 34.7%, respectively. However,
contradictory to other studies that have reported an increased risk of mortality among
patients with co-occurring diabetes and TB[52], Magee et al. found that diabetes was not
associated with increased mortality (aOR 1.05; 95%CI 0.60-1.84)[53].
The association between diabetes and TB has been known about for centuries and
was even suggested during Roman times[11]. Studies have demonstrated a significant
association between LTBI and active TB and diabetes. In a 2011 cross-sectional study
conducted by Hensel et al., newly arrived refugees at a health clinic in Atlanta, Georgia
were screened for diabetes, pre-diabetes and LTBI. Researchers determined diabetes and
pre-diabetes by measuring HbA1c (glycated hemoglobin) levels and screened for LTBI
using QFT-GIT. The prevalence of LTBI among patients with diabetes (43.4%) and prediabetes (39.1%) was found to be significantly higher (p<0.01) than among patients
without diabetes (25.9%). Hensel et al. hypothesized that the reason for a higher
10

prevalence of LTBI among patients with diabetes may be due to dysglycemia causing
immunologic dysfunction[19].
In a cohort study conducted in the country of Georgia during 2011-2014, Magee
et al. evaluated 318 new TB patients (with no previous history of TB) for diabetes and
pre-diabetes using HbA1c measurements. Researchers found the prevalence of diabetes
and pre-diabetes to be fairly high among the new TB patients – 11.6% and 16.4%,
respectively. The total combined prevalence of new TB patients with diabetes or prediabetes was determined to be 28%[54].
In a systematic review of 13 observational studies of the association between
diabetes and active TB, Jeon et al. reported that all 13 studies found diabetes to be
associated with an increased risk of TB. A meta-analysis of the results of the three cohort
studies found the relative risk of TB among patients with diabetes to be 3.11 (95%CI
2.27-4.26) times the relative risk among patients without diabetes[16]. Contradicting
results were seen in a 2011 case-control study conducted in Denmark by Leegard et al.
Researchers found the odds of active TB among patients with diabetes to only be 1.18
(95%CI 0.96-1.45) times the odds of active TB among patients without diabetes. This
finding of only a “modestly increased” risk of TB in patients with diabetes may be due to
the study being conducted in Denmark, a country with a low burden of TB[13]. Though
many studies have shown an association between active TB and diabetes, there is an
extreme lack of studies on the association between LTBI and diabetes.
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2.4

Summary of Literature Review
Highlights from the literature review of previous studies include:


Immune dysfunction associated with co-occurring diabetes and LTBI
increases the risk of progression to active TB



Poor glycemic control (higher HbA1c levels) may be associated with an
increased risk of TB



It has been well-established that active TB is associated with diabetes, but
there are is a lack of studies investigating the association between LTBI
and diabetes
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CHAPTER III
MANUSCRIPT
Introduction
There were an estimated 10.4 million incident cases of active tuberculosis (TB) globally
in 2015, and 1.4 million deaths attributable to TB[1]. In addition, about one-fourth of the global
population has prevalent latent tuberculosis infection (LTBI)[55]. Although the lifetime risk of
reactivation of LTBI to TB disease only occurs in approximately 10% of infected individuals [2],
the risk of progression to TB is higher in individuals with comorbidities, such as HIV[5] and
diabetes mellitus[6-9, 11, 19, 45]. Individuals with diabetes have approximately three times the
risk of active TB compared to the general population[6, 7, 9, 10]. As a consequence of this
increased risk of active TB, an estimated 15% of TB cases are attributed to diabetes[7, 15].
Of public health concern, the global diabetes epidemic is steadily increasing[6, 11, 12]. In
2014, an estimated 415 million adults were living with diabetes, and the prevalence of diabetes is
projected to reach 642 million adults globally by 2040[14]. Additionally, an estimated 95% of
TB patients reside in low- and middle-income countries, and the largest projected increases in
diabetes will occur in these same countries[11, 12].
Although existing evidence has demonstrated a relationship between diabetes and active
TB, it is unclear whether diabetes also increases the risk of LTBI. The limited studies that
examined the relationship between diabetes and LTBI have reported substantial heterogeneity
across studies[56] and have not accounted for confounding by other clinical comorbidities such
as kidney disease or hepatitis[18, 57]. Previous studies that reported a significant association
between diabetes and LTBI were not widely generalizable and mostly have not used reliable
measures of diabetes and LTBI[56]. Knowledge on the direction of the association between
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diabetes and LTBI is also lacking. An increased risk of LTBI in patients with diabetes would
have major clinical implications for TB and diabetes, especially with the expected increase in
global diabetes prevalence. To address the gap in knowledge related to diabetes and LTBI, we
aimed to determine the association between prediabetes and diabetes and LTBI using the
National Health and Nutrition Examination Survey (NHANES), a study with data that are
representative of the US population.
Methods
We conducted a cross-sectional study using data collected as part of the NHANES 20112012 cycle, which is the most recent cycle that includes the QuantiFERON®-TB Gold In Tube
(QFT-GIT) test as a measure of LTBI status. Briefly, NHANES is a nationally representative
survey of US non-institutionalized civilians that includes an in-person home interview followed
by a health examination. Details of NHANES methodology have been published previously[58].
In the 2011-2012 survey cycle, a total of 13,431 individuals were selected for participation from
30 different locations in the United States. Of those individuals, 9,756 completed the in-person
home interview and 9,338 completed the in-person home interview and received the health
examination[59].
Study Design and Participants
Eligible participants for our study were adults aged 20 years and older who completed the
home questionnaire and the health examination. Eligible participants were also required to have
both a valid TB test result and a valid diabetes status. A positive or negative result for the QFTGIT test was considered a valid result. Participants who were missing a result for the QFT-GIT
test or who had an indeterminate result for the test were excluded from the study. Participants
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who had a glycated hemoglobin (HbA1c) measurement and/or information regarding selfreported diabetes status were considered to have a valid diabetes status. Participants who were
missing both an HbA1c measurement and information regarding self-reported diabetes status
were excluded from the study.
Biological specimen collection was performed in specially equipped mobile examination
centers (MECs)[58]. Blood samples were drawn by a phlebotomist and refrigerated or frozen
before being shipped and urine samples were also collected from participants. Samples were
transported to laboratories across the United States for processing[60], except samples for QFTGIT testing, which were sent to only one Clinical Laboratory Improvement Act-certified
laboratory for processing[18].
Study Measures and Definitions
Diabetes status of participants was defined by self-reported diabetes status and HbA1c
levels. Participants who indicated that they had previously been diagnosed by a healthcare
professional to have diabetes were classified as having diabetes regardless of HbA1c
measurement. If participants did not indicate a previous history of diabetes diagnosis, diabetes
status was then classified by HbA1c as no diabetes (≤5.6%), prediabetes (5.7-6.4%), or diabetes
(≥6.5%) according to the American Diabetes Association guidelines[61]. Participants with
diabetes were further classified as having diagnosed or undiagnosed diabetes. Diagnosed
diabetes was classified as self-reporting diabetes, and undiagnosed diabetes was classified as
self-reporting not having diabetes but having an HbA1c level in the range for diabetes (≥6.5%).
Among participants with self-reported diabetes, length of time since initial diabetes diagnosis
and information regarding diabetes medication were also assessed via questionnaire. Use of
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diabetes medications was determined by responses to self-reported questions on the use of
insulin and oral agents[62].
Latent TB infection was defined by QFT-GIT according to manufacturer instructions.
Results were interpreted according to guidelines from the Centers for Disease Control and
Prevention (CDC) for using interferon-gamma release assays (IGRAs)[63]. Participants with a
positive QFT-GIT result were classified as LTBI positive, participants with a negative QFT-GIT
result were classified as LTBI negative, and participants with an indeterminate QFT-GIT result
were classified as missing.
Participants who self-reported they had ever been told by a health care professional to
have active TB were defined as having a history of active TB. Body mass index (BMI) ranges
were categorized as underweight (<18.5), normal weight (18.5-24.9 kg/m2), overweight (25.029.9 kg/m2), or obese (≥30 kg/m2) according to CDC guidelines[64]. Age ranges were
categorized as young adult (20-34 years), middle-aged (35-64 years), or elderly (65 years and
older). Current smokers were defined as participants who self-reported use of 100 cigarettes in
their lifetime and self-reported currently smoking. Former smokers were defined as those who
reported smoking 100 cigarettes in their lifetime but did not currently smoke cigarettes.
Participants who had not smoked 100 cigarettes in their lifetime were defined as never smokers
[65, 66].
Urine samples were analyzed for albumin creatinine ratio (ACR), and ACR levels were
categorized as normal to mildly increased (<30mg/g), moderately increased (30-300mg/g), or
severely increased (>300mg/g) according to National Kidney Foundation guidelines for
albuminuria categories in chronic kidney disease[67]. Hepatitis B virus (HBV) core antibody
(anti-HBc) and surface antigen (HBsAg) response were determined using the VITROS Anti-HBc
20

assay and HBsAg assay, respectively; results were defined as positive or negative. The HBsAg
assay was only performed for participants that tested positive for anti-HBc; participants with a
negative result for anti-HBc were defined as negative for HBsAg. Hepatitis C antibody (antiHCV) response was determined using the VITROS Anti-HCV assay; results were defined as
positive or negative. Non-fasting blood samples were analyzed for total cholesterol and highdensity lipoprotein (HDL) cholesterol[68]. Our study categorized total cholesterol levels as
desirable (<200mg/dL), borderline high (200-239mg/dL), or high (≥240mg/dL) according to
National Institutes of Health guidelines[69]. Our study categorized HDL cholesterol levels as
major risk factor for heart disease (<40mg/dL), borderline (40-59mg/dL), or protective against
heart disease (≥60mg/dL) according to Medline Plus guidelines[70]. Responses of “don’t know”
or “refused” were recoded as missing for all variables.
Statistical Analyses
To examine the association between diabetes and LTBI we used bivariate analyses and
multivariable logistic regression. The Rao-Scott chi-square test was used to analyze all bivariate
associations between participant characteristics and LTBI and diabetes. To examine the
prevalence of diabetes and LTBI in the United States population, we reported weighted
prevalence estimates and 95% confidence intervals (CI). Taylor series method was used to
estimate variance for all prevalence estimates[71]. Multivariable logistic regression models were
used to estimate the adjusted odds ratio (aOR) and 95% CI between diabetes and LTBI and were
adjusted for potential confounders. Covariates included in multivariable models as confounders
were chosen from observed bivariate associations with diabetes and LTBI, previous study
findings, and causal model theory (directed acyclic graphs) [72]. In multivariable models,
multiplicative statistical interaction was assessed to determine if the association between diabetes
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and LTBI was modified by obesity or HDL cholesterol. In a subgroup analysis, we also
examined the bivariate association between participant characteristics and LTBI only among
individuals with diabetes. All analyses were performed using SAS version 9.4 and accounted for
the weighted stratified probability sample design of NHANES using SAS survey procedures[73].
Because medical examination data were used during the analyses, we used the weight variable
WTMEC2YR to obtain accurate prevalence estimates and measures of association. A two-sided
p-value <0.05 was considered statistically significant for all tests.
Sensitivity Analysis
We performed sensitivity analyses to assess potential error due to 1) misclassification of
diabetes status and 2) covariate misspecification in multivariable models. To assess diabetes
misclassification, we re-examined the diabetes-LTBI association after adding fasting blood
glucose (prediabetes 100-125mg/dL, or diabetes ≥126mg/dL) to our primary diabetes definition
which used self-report and HbA1c only[61]. In the second sensitivity analysis we specified
several subsets of adjusted multivariable models to provide a range of plausible aORs and
95%CI for the association between diabetes and LTBI.
Results
Study Participants
Of 9,756 NHANES 2011-2012 participants, 5,560 (57.0%) were aged 20 years or older
and thus eligible for our study. A total of 4,958 (89.2%) participants had both valid QFT-GIT
results and information on self-reported diabetes status and/or HbA1c results and were included
in these analyses (Figure 1). Before accounting for selection weights, 793 eligible participants
had diabetes, 513 had LTBI, and 127 had both diabetes and LTBI.
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Prevalence of Diabetes and Latent TB Infection
The estimated prevalence of diabetes among adults in the United States population was
11.4% (95%CI 9.8-13.0%) and the prevalence of prediabetes was 22.1% (95%CI 20.5-23.8%)
(Table 1). The prevalence of diabetes was highest among the elderly (22.9%; 95%CI 19.825.9%), people with obesity (20.4%; 95%CI 17.3-23.5%), those with less than a 9th grade
education (25.2%; 95%CI 18.2-32.2%), severely increased ACRs (46.9%; 95%CI 33.7-60.1%),
hepatitis C (19.8%; 95%CI 7.1-32.5%), and hypertension (23.3%; 95%CI 20.8-25.9%).
Our results estimated that the prevalence of LTBI among adults in the United States was
5.9% (95%CI 4.9-7.0%) (Table 2). Prevalence of LTBI was highest among the elderly (8.8%;
95%CI 6.6-10.9%), the foreign-born (17.2%; 95%CI 14.3-20.0%), those with less than a 9th
grade education (17.9%; 95%CI 13.2-22.7%), Hispanics (12.9%; 95%CI 10.4-15.4%),nonHispanic Asians (20.3%; 95%CI 16.8-23.8%), and those who reported a previous history of
active TB (42.7%; 95%CI 24.1-61.2). LTBI prevalence was also high among those with high
(>300mg/g) ACR (12.9%; 95%CI 6.7-19.2%), those who tested positive for anti-HBc (18.0%;
95%CI 11.6-24.4%), and those who tested positive for HBsAg (23.0%; 95%CI 8.2-37.7%).
The prevalence of LTBI was significantly higher among adults with diabetes (11.6%;
95%CI 7.9-15.3%) compared to those without diabetes (4.6%; 95%CI 3.7-5.6%). LTBI
prevalence was also higher among those with prediabetes (7.0%; 95%CI 5.2-8.7%) compared to
those without diabetes, though the difference was not statistically significant. Adults with
diabetes and prediabetes had significantly higher crude odds of LTBI (diabetes: crude OR 2.70;
95%CI 1.76-4.14; prediabetes: crude OR 1.54; 95%CI 1.24-1.91) compared to those without
diabetes (Table 3). Reported inversely, among those with LTBI the prevalence of diabetes was
22.2% (95%CI 16.6-27.8%) and the prevalence of prediabetes was 25.9% (95%CI 22.1-29.7%).
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Among those without LTBI the prevalence of diabetes was 10.7% (95%CI 9.0-12.4%) and the
prevalence of prediabetes was 21.9% (95%CI 20.3-23.6%).
Multivariable Models Results
Multivariable logistic models were examined adjusting for age, sex, smoking status,
history of active TB, and foreign born status. Adults with diabetes had significantly higher odds
of LTBI (aOR 1.90; 95%CI 1.15-3.14) compared to adults without diabetes (Table 3). Those
previously diagnosed with diabetes had significantly higher odds of LTBI (aOR 1.75; 95%CI
1.09-2.80) compared to adults without diabetes, as did adults with previously undiagnosed
diabetes (aOR 1.96; 95%CI 1.05-3.68). The odds of LTBI among adults with prediabetes (aOR
1.15; 95%CI 0.90-1.47) was not significantly higher than among adults without diabetes.
We found no indication of significant multiplicative interaction. Although not
significantly different from each other, the association between diabetes and LTBI tended to be
greater among those with obesity (aOR 2.22; 95%CI 1.08-4.54) compared to those without
obesity (aOR 1.48; 95%CI 0.85-2.58) (data not shown). Similarly, the association between
diabetes and LTBI was non-significantly greater among those with higher HDL (≥60mg/dL)
levels (aOR 2.77; 95%CI 1.13-6.84) compared to those with lower HDL (<60mg/dL) levels
(aOR 1.80; 95%CI 0.99-3.29).
Subgroup Analysis of Adults with Diabetes
Among adults with diabetes, an estimated 19.9% (95%CI 15.3-24.4%) were previously
undiagnosed (Table 4). Prevalence of LTBI was non-significantly (p-value=0.24) different
among adults with previously undiagnosed diabetes (14.4%; 95%CI 6.7-22.2%) compared to
adults who had been previously diagnosed (10.9%; 95%CI 7.4-14.4%). LTBI prevalence was
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significantly higher (p-value=0.03) among adults who reported not using insulin (12.9%; 95%CI
8.5-17.3%) compared to adults who reported using insulin (7.3%; 95%CI 3.1-11.4). Among
those with diabetes, LTBI prevalence was found to be highest among Hispanics (24.3%; 95%CI
12.4-36.2%), non-Hispanic Asians (27.5%; 95%CI 19.0-35.9%), those born outside of the United
States (30.2; 95%CI 18.8-41.6%), and those with a positive test result for anti-HBc (20.8%;
95%CI 8.9-32.7%).
Sensitivity Analyses
In our sensitivity analysis to assess potential misclassification of diabetes using FBG in
addition to self-report and HbA1c, adults with diabetes had significantly higher crude odds of
LTBI (crude OR 2.43; 95%CI 1.32-4.49) compared to those without diabetes (data not shown).
Adults with prediabetes had non-significantly higher crude odds of LTBI (crude OR 1.21;
95%CI 0.74-2.00) compared to those without diabetes. After adjusting for age, sex, smoking
status, history of active TB, and foreign born status, adults with diabetes had a non-significant
higher odds of LTBI (aOR 1.36; 95%CI 0.70-2.65) compared to those without diabetes.
In our sensitivity analysis to assess covariate misspecification of adjusted models, we found
adjusted odds ratios that ranged from 1.49 (95%CI 0.83-2.68) to 2.20 (95%CI 1.22-3.96) for the
odds of LTBI in adults with diabetes compared to those without diabetes (Supplemental Table
1). We found adjusted odds ratios that ranged from 0.95 (95%CI 0.75-1.21) to 1.25 (95%CI
0.93-1.68) for the odds of LTBI in adults with prediabetes compared to those without diabetes;
however, none were statistically significant.
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Discussion
We used data nationally representative of the US population to examine the association
between LTBI and diabetes and found a robust relationship between the two diseases. We
reported that the prevalence of LTBI among adults with diabetes was more than twice the
prevalence of those without diabetes. Similarly, we found that more than one-fifth of adults with
LTBI had diabetes. We did not find significant differences in LTBI prevalence among those who
were previously diagnosed compared to those who were previously undiagnosed. We also did
not find significant differences in LTBI prevalence among those with prediabetes compared to
those without diabetes. To our knowledge, this study is the largest and most generalizable
analysis to compare the prevalence of LTBI among adults with and without diabetes and
prediabetes.
Our results are consistent with the findings of previous studies. In a systematic review
conducted by Lee et al., the meta-analysis included findings from one cohort study and 12 crosssectional studies investigating the association between diabetes and LTBI. From the 12 crosssectional studies, researchers calculated a pooled odds ratio of 1.18 (95%CI 1.06-1.30),
indicating a slight yet significant increased odds of LTBI among patients with diabetes compared
to patients without diabetes[56]. A limitation of several studies reviewed in Lee et al.’s
systematic review and meta-analysis was the potential misclassification of LTBI due to
measurement error associated with the TST (tuberculin skin test). Unlike many previous studies,
our study relied upon the use of QFT-GIT which is not affected by the Bacillus Calmette-Guérin
(BCG) vaccine. Our national estimates of LTBI prevalence were similar to previously reported
estimates[18, 28]
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Our results were similar to a study conducted by Hensel et al. in the metropolitan area of
Atlanta, Georgia[19]. This study also utilized both HbA1c and QFT-GIT to determine diabetes
status and LTBI status, respectively. Hensel et al. found a nearly doubled prevalence of LTBI
among patients with diabetes compared to those without diabetes[19]. Unlike our study,
however, the Atlanta study was not generalizable to the US adult population, as it only included
recently arrived refugees to the United States[19]. As with the Atlanta study, we found no
significant difference in the prevalence of LTBI among patients with previously undiagnosed
diabetes compared to those with previously diagnosed diabetes[19].
Although the causal mechanisms that result in increased co-occurrence of LTBI and
diabetes remain to be definitively established, there are relevant biologic hypotheses that may
explain how LTBI may increase the risk of diabetes and vice-versa. Some LTBI granulomas on
the spectrum of high MTB activity include bacterial replication and likely result in proximal
immune signaling, a phenomena which may persist in adipose tissue[74]. Secretion of proinflammatory adipokines and cytokines within adipocytes could interfere with insulin regulation
and contribute to diabetes risk[30, 75]. If LTBI contributes to immune activation within visceral
adipose tissue, it would likely increase the risk of diabetes or prediabetes. Alternatively, chronic
low-grade inflammation and immunopathology associated with diabetes and prediabetes [31, 33]
may contribute to susceptibility to TB infection[8, 9].
Our study was subject to several limitations. First, there may have been misclassification
of participant characteristics. For example, self-reported information on smoking status was
determined via participant responses to a questionnaire, so smokers may have reported not
smoking due to social stigma. While diabetes and LTBI status may also be subject to
misclassification, we defined these primary study variables using currently recommended
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clinical measures (HbA1c and QFT-GIT)[76, 77]. By using the QFT-GITs instead of the TST to
measure LTBI, we avoided potential cross-reaction with antigens found in the BCG vaccine,
commonly used outside the United States [29, 77]. However, we did not account for discordance
between QFT-GIT and TST, and therefore some misclassification of LTBI may have occurred.
Second, in this study we were unable to adjust for the probability being exposed to someone with
active TB. Although previous history of active TB was assessed via questionnaire and found to
be associated with LTBI but not diabetes status, the inability to adjust for probability of exposure
to TB may have distorted our estimated association between LTBI and diabetes. Nonetheless, we
did adjust for several other key confounding factors such as smoking, age, and foreign born
status. We also were able to assess the distribution of other underlying infections, such as
hepatitis B and C and kidney disease, and found no evidence of confounding. Third, our study
was a cross-sectional design, and as such we were unable to determine the temporal relationship
between LTBI and diabetes. For example, our results are unable to differentiate whether the
observed association was due to an increased risk of LTBI from diabetes or if LTBI may increase
the risk of diabetes. Longitudinal studies are needed to investigate the temporal association
between LTBI and diabetes.
Conclusion
This study reported that diabetes was significantly associated with an increased odds of
LTBI prevalence in US adults, even after adjusting for key confounding factors. Overall, more
than one-fifth of all adults with LTBI had diabetes. Information from this study greatly improves
our understanding of the intersection of the TB and diabetes epidemics. With the increasing
prevalence of diabetes in areas with the highest burden of TB, targeted efforts may be needed to
address the co-infection of diabetes and LTBI to prevent an increase in TB incidence worldwide.
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Table 1: Weighted prevalence of diabetes and prediabetes among the civilian, non-institutionalized
United States population, adults 20 years and older, 2011-2012
Participant
Characteristics

Age (years)
20 – 34
35 – 64
≥65
BMI4
<18.5
18.5 – 24.9
25.0-29.9
≥30.0
Foreign Born5
No
Yes
LTBI6
Positive
Negative
TST7
Positive
Negative
HbA1c (%)8
<5.7
5.7-6.4
≥6.5
Education
<9th Grade
9th – 12th
HS Grad/GED
Some College
≥College Grad
Race/Ethnicity
Hispanic
NH White
NH Black
NH Asian
Sex
Female
Male
Smoking Status9
Current
Former
Never

Diabetes1
% (95% CI)
11.4
(9.8-13.0)

Prediabetes2
% (95% CI)
22.1
(20.5-23.8)

No Diabetes
% (95% CI)
66.5
(64.2-68.8)

pvalue3

27.5 (23.1-31.9)
54.9 (51.8-57.9)
17.6 (15.3-19.9)

2.0 (1.2-2.8)
12.4 (10.2-14.6)
22.9 (19.8-25.9)

9.0 (7.3-10.7)
24.0 (20.6-27.3)
36.9 (32.8-41.0)

89.0 (87.0-91.0)
63.6 (60.0-67.1)
40.3 (34.8-45.7)

<0.01

1.8 (1.3-2.2)
29.4 (26.1-32.6)
33.5 (30.7-36.3)
35.4 (32.3-38.5)

4.2 (0-8.8)
5.1 (3.4-6.9)
7.7 (6.7-8.6)
20.4 (17.3-23.5)

8.0 (2.1-13.9)
17.6 (14.0-21.2)
22.8 (19.2-26.3)
26.1 (23.1-29.1)

87.8 (81.0-94.5)
77.3 (72.9-81.7)
69.6 (66.1-73.0)
53.5 (49.3-57.6)

<0.01

82.1 (77.9-86.3)
17.9 (13.7-22.1)

11.0 (9.2-12.8)
13.2 (11.3-15.0)

22.0 (20.0-23.9)
22.7 (19.8-25.6)

67.0 (64.4-69.6)
64.1 (61.1-67.1)

0.12

5.9 (4.9-7.0)
94.1 (93.0-95.1)

22.2 (16.6-27.8)
10.7 (9.0-12.4)

25.9 (22.1-29.7)
21.9 (20.3-23.6)

51.9 (45.8-58.0)
67.4 (65.0-69.8)

<0.01

4.7 (3.0-6.4)
95.3 (93.6-97.0)

15.5 (9.4-21.6)
11.3 (9.7-13.0)

29.2 (18.5-39.9)
22.2 (20.2-24.2)

55.3 (46.6-63.9)
66.5 (64.0-69.9)

0.11

67.1 (64.9-69.3)
24.8 (22.7-26.9)
8.1 (6.9-9.3)

0.91 (0.50-1.3)
10.8 (7.8-13.8)
100 (100-100)

0 (0-0)
89.2 (86.2-92.2)
0 (0-0)

99.1 (98.7-99.5)
0 (0-0)
0 (0-0)

5.7 (4.5-7.0)
10.5 (7.6-13.5)
20.2 (17.2-23.2)
32.2 (29.0-35.3)
31.4 (26.1-36.7)

25.2 (18.2-32.2)
15.0 (13.5-16.5)
14.7 (11.1-18.2)
10.0 (8.3-11.7)
7.0 (4.2-9.8)

29.2 (24.0-34.4)
26.6 (21.9-31.2)
27.2 (21.1-33.2)
20.7 (17.0-24.5)
17.5 (14.2-20.8)

45.6 (39.3-52.0)
58.4 (53.7-63.1)
58.2 (52.1-64.2)
69.3 (66.1-72.5)
75.5 (70.9-80.1)

<0.01

14.7 (9.2-20.2)
68.8 (60.2-77.3)
11.3 (6.5-16.1)
5.2 (3.2-7.1)

13.1 (10.5-15.6)
9.4 (7.6-11.2)
17.9 (14.2-21.6)
12.9 (9.8-16.0)

21.8 (19.2-24.3)
20.9 (18.4-23.5)
30.0 (27.1-32.9)
22.9 (18.3-27.5)

65.1 (62.1-68.2)
69.6 (66.2-73.1)
52.1 (48.7-55.6)
64.2 (57.4-71.0)

<0.01

52.2 (50.5-53.9)
47.8 (46.1-49.5)

11.1 (9.3-12.8)
11.8 (9.7-13.8)

22.2 (19.7-24.8)
22.0 (20.0-24.0)

66.7 (63.5-69.9)
66.3 (63.3-69.2)

0.82

19.5 (17.2-21.7)
24.3 (21.6-26.9)
56.2 (53.3-59.1)

10.5 (8.8-12.3)
15.2 (11.7-18.8)
10.2 (8.2-12.2)

27.1 (21.4-32.8)
23.6 (20.2-26.9)
20.0 (17.4-22.7)

62.4 (57.0-67.7)
61.2 (56.3-66.1)
69.8 (66.6-73.0)

<0.01

Totals for
Population
N=4,958
% (95% CI)
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Previous TB10
Yes
No
TB Meds11
Yes
No
Ratio of Family Income
to Poverty12
0-0.99
1-1.99
2-2.99
3-3.99
4-4.99
≥5
Albumin/Creatinine
Ratio (mg/g)13
<30
30 – 300
>300
HepB Core Ab14
Positive
Negative
HepB Surface Ag15
Positive
Negative
HepC Ab (confirmed)16
Positive
Negative
Self-reported
Hypertension17
Yes
No
Total Bilirubin
(mg/dL)18
Normal
Not Normal
Total Cholesterol
(mg/dL)19
<200
200-239
≥240
HDL Cholesterol
(mg/dL)20
<40
40 – 59
≥60

0.40 (0.22-0.58)
99.6 (99.4-99.8)

7.3 (0-16.3)
11.4 (9.8-13.0)

30.8 (14.2-47.4)
22.1 (20.4-23.8)

61.9 (45.0-78.8)
66.5 (64.1-68.8)

0.59

0.24 (0.12-0.36)
99.8 (99.6-99.9)

4.7 (0-12.2)
11.4 (9.8-13.0)

32.8 (4.4-61.2)
22.1 (20.4-23.8)

62.5 (32.5-92.5)
66.5 (64.1-68.8)

0.63

17.2 (13.8-20.6)
21.1 (18.1-24.2)
14.3 (12.1-16.4)
12.1 (9.1-15.1)
10.7 (8.5-12.9)
24.6 (19.6-29.6)

14.9 (11.6-18.1)
14.9 (12.3-17.5)
11.9 (7.9-15.8)
9.4 (7.2-11.6)
13.6 (5.6-21.5)
5.4 (3.0-7.8)

20.5 (15.6-25.3)
24.6 (20.4-28.8)
24.0 (19.1-28.9)
18.5 (14.6-22.4)
17.8 (13.3-22.2)
21.5 (17.2-25.9)

64.7 (57.9-71.5)
60.5 (55.3-65.7)
64.1 (57.8-70.5)
72.1 (67.7-76.6)
68.7 (60.0-77.3)
73.1 (67.1-79.0)

90.4 (89.2-91.6)
8.3 (7.4-9.2)
1.3 (0.94-1.7)

9.2 (7.9-10.5)
28.7 (23.5-33.9)
46.9 (33.7-60.1)

21.9 (20.1-23.8)
24.8 (22.4-27.1)
21.0 (8.6-33.3)

68.9 (66.6-71.2)
46.5 (40.5-52.5)
32.1 (16.2-48.1)

<0.01

4.6 (3.6-5.5)
95.4 (94.5-96.4)

19.1 (13.1-25.1)
10.8 (9.3-12.3)

28.0 (20.3-35.7)
21.7 (19.9-23.6)

52.9 (46.2-59.6)
67.5 (65.2-69.8)

<0.01

0.34 (0.20-0.48)
99.7 (99.5-99.8)

8.6 (1.4-15.8)
11.2 (9.7-12.7)

27.7 (12.9-42.4)
22.0 (20.3-23.7)

63.8 (45.9-81.6)
66.9 (64.6-69.1)

<0.01

1.7 (1.0-2.3)
98.3 (97.7-99.0)

19.8 (7.1-32.5)
11.1 (9.7-12.5)

17.5 (11.4-23.6)
22.0 (20.2-23.9)

62.7 (46.9-78.4)
66.9 (64.6-69.2)

0.01

31.5 (28.4-34.7)
68.5 (65.3-71.6)

23.3 (20.8-25.9)
5.9 (4.8-7.0)

29.2 (26.6-31.8)
18.9 (17.2-20.6)

47.5 (44.1-50.8)
75.2 (73.2-77.3)

<0.01

98.7 (98.0-99.4)
1.3 (0.59-2.0)

11.2 (9.6-12.7)
5.3 (0.21-10.4)

22.1 (20.5-23.7)
14.3 (1.7-26.9)

66.7 (64.4-69.1)
80.4 (67.0-93.9)

0.11

56.9 (55.0-58.8)
30.1 (28.4-31.7)
13.0 (11.4-14.7)

12.7 (11.2-14.1)
8.9 (6.6-11.3)
9.6 (6.4-12.9)

19.1 (17.0-21.2)
24.4 (20.8-28.1)
29.2 (24.9-33.7)

68.2 (65.4-71.0)
66.6 (61.9-71.3)
61.1 (56.1-66.1)

<0.01

17.4 (14.7-20.1)
54.7 (51.9-57.6)
27.9 (25.5-30.2)

18.9 (13.4-24.5)
11.8 (10.5-13.1)
5.1 (3.2-6.9)

25.4 (22.2-28.6)
23.3 (21.1-25.5)
17.5 (13.4-21.6)

55.7 (48.6-62.7)
64.9 (62.3-67.5)
77.4 (72.7-82.1)

<0.01

Table 1 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TSTtuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core
antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody
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<0.01

1: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that
he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who self-reported
diabetes were classified as having diabetes regardless of HbA1c.
2: Prediabetes determined according to American Diabetes Association guidelines[61].
3: All p-values obtained using Rao-Scott chi-square.
4: BMI categories defined according to CDC guidelines[64].
5. Foreign born individuals include those who reported being born in one of the five United States territories.
6: Positive LTBI defined by positive QFT-GIT result; negative LTBI defined by negative QFT-GIT result.
7: Positive TST defined as an induration >10mm[78].
8: HbA1c categories determined according to American Diabetes Association guidelines[61].
9: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked
at least 100 cigarettes in their lifetime defined as never having smoked[65, 66].
10: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?”[79]11:
Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or
TB?”; specific medicine type not asked[79].
12: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and
Human Services used as poverty measure to calculate ratio of family income to poverty[80].
13: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for
albuminaria categories in chronic kidney disease (CKD)[67].
14: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[81].
15 : HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by
response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for
HBsAg[81].
16: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with
repeatedly positive reactions to Anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0
Strip[82].
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17: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had hypertension/high blood pressure)[83].
18: Categories for Total Bilirubin defined according to Medline Plus guidelines[84].
19: Categories for Total Cholesterol defined according to National Institute of Health guidelines[69].
20: Categories for HDL Cholesterol defined according to Medline Plus guidelines as follows[70].
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Table 2: Weighted prevalence of latent tuberculosis infection (LTBI) among the civilian, noninstitutionalized United States population, adults 20 years and older, 2011-2012
Participant
Characteristics

Age (years)
20 – 34
35 – 64
≥65
BMI4
<18.5
18.5 – 24.9
25.0-29.9
≥30.0
Foreign Born5
No
Yes
TST6
Positive
Negative
Diabetes7
No Diabetes
Prediabetes
Diabetes
HbA1c (%)8 <5.7
5.7-6.4
≥6.5
Education
<9th Grade
9th – 12th
HS Grad/GED
Some College
≥College Grad
Race/Ethnicity
Hispanic
NH White
NH Black
NH Asian
Sex
Female
Male
Smoking Status9
Current
Former
Never
Previous TB10

Totals for
Population
N=4,958
% (95% CI)

LTBI Positive 1
% (95% CI)
5.9
(4.9-7.0)

LTBI Negative2
% (95% CI)
94.1
(93.0-95.1)

p-value3

27.5 (23.1-31.9)
54.9 (51.8-57.9)
17.6 (15.3-19.9)

3.3 (2.5-4.1)
6.4 (4.7-8.1)
8.8 (6.6-10.9)

96.7 (95.9-97.5)
93.6 (91.9-95.3)
91.2 (89.1-93.4)

<0.01

1.8 (1.3-2.2)
29.4 (26.1-32.6)
33.5 (30.7-36.3)
35.4 (32.3-38.5)

7.9 (2.0-13.9)
6.4 (4.5-8.3)
5.6 (4.3-6.9)
5.8 (4.7-7.0)

92.1 (86.1-98.0)
93.6 (91.7-95.5)
94.4 (93.1-95.7)
94.2 (93.0-95.3)

0.68

82.1 (77.9-86.3)
17.9 (13.7-22.1)

3.5 (2.5-4.6)
17.2 (14.3-20.0)

96.5 (95.4-97.5)
82.8 (80.0-85.7)

<0.01

4.7 (3.0-6.4)
95.3 (93.6-97.0)

46.2 (40.1-52.4)
3.6 (2.7-4.4)

53.8 (47.6-59.9)
96.4 (95.6-97.3)

<0.01

66.5 (64.2-68.8)
22.1 (20.5-23.8)
11.4 (9.8-13.0)

4.6 (3.7-5.6)
7.0 (5.2-8.7)
11.6 (7.9-15.3)

95.4 (94.4-96.3)
93.0 (91.3-94.8)
88.4 (84.7-92.1)

<0.01

67.1 (64.9-69.3)
24.8 (22.7-26.9)
8.1 (6.9-9.3)

4.7 (3.7-5.6)
7.7 (6.0-9.5)
10.9 (7.1-14.8)

95.3 (94.4-96.3)
92.3 (90.5-94.0)
89.1 (85.2-92.9)

<0.01

5.7 (4.5-7.0)
10.5 (7.6-13.5)
20.2 (17.2-23.2)
32.2 (29.0-35.3)
31.4 (26.1-36.7)

17.9 (13.2-22.7)
7.7 (5.4-10.0)
7.1 (4.7-9.5)
3.5 (2.2-4.7)
5.0 (3.4-6.6)

82.1 (77.3-86.8)
92.3 (90.0-94.6)
92.9 (90.5-95.3)
96.5 (95.3-97.8)
95.0 (93.4-96.6)

<0.01

14.7 (9.2-20.2)
68.8 (60.2-77.3)
11.3 (6.5-16.1)
5.2 (3.2-7.1)

12.9 (10.4-15.4)
3.1 (2.2-4.1)
8.0 (6.0-9.9)
20.3 (16.8-23.8)

87.1 (84.6-89.6)
96.9 (95.9-97.8)
92.0 (90.1-94.0)
79.7 (76.2-83.4)

<0.01

52.2 (50.5-53.9)
47.8 (46.1-49.5)

5.0 (3.9-6.2)
6.9 (5.7-8.2)

95.0 (93.8-96.1)
93.1 (91.8-94.3)

<0.01

19.5 (17.2-21.7)
24.3 (21.6-26.9)
56.2 (53.3-59.1)

6.7 (4.3-9.1)
7.1 (4.8-9.5)
5.2 (4.2-6.1)

93.3 (90.9-95.7)
92.9 (90.5-95.2)
94.8 (93.9-95.8)

0.15
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Yes
No
TB Meds11
Yes
No
Ratio of Family Income
to Poverty12
0-0.99
1-1.99
2-2.99
3-3.99
4-4.99
≥5
Albumin/Creatinine
Ratio (mg/g)13
<30
30 – 300
>300
HepB Core Ab14
Positive
Negative
HepB Surface Ag15
Positive
Negative
HepC Ab (confirmed)16
Positive
Negative
Self-reported
Hypertension17
Yes
No
Total Bilirubin
(mg/dL)18
Normal
Not Normal
Total Cholesterol
(mg/dL)19
<200
200-239
≥240
HDL Cholesterol
(mg/dL)20
<40
40 – 59
≥60

0.40 (0.22-0.58)
99.6 (99.4-99.8)

42.7 (24.1-61.2)
5.8 (4.8-6.8)

57.3 (38.8-75.9)
94.2 (93.2-95.2)

<0.01

0.24 (0.12-0.36)
99.8 (99.6-99.9)

48.2 (24.6-71.7)
5.8 (4.8-6.8)

51.8 (28.3-75.4)
94.2 (93.2-95.2)

<0.01

17.2 (13.8-20.6)
21.1 (18.1-24.2)
14.3 (12.1-16.4)
12.1 (9.1-15.1)
10.7 (8.5-12.9)
24.6 (19.6-29.6)

8.5 (6.3-10.7)
7.8 (6.1-9.5)
5.4 (2.3-8.5)
4.7 (2.7-6.6)
2.9 (0.94-4.9)
4.1 (2.3-5.9)

91.5 (89.3-93.7)
92.2 (90.5-93.9)
94.6 (91.5-97.7)
95.3 (93.4-97.3)
97.1 (95.1-99.1)
95.9 (94.1-97.7)

<0.01

90.4 (89.2-91.6)
8.3 (7.4-9.2)
1.3 (0.94-1.7)

5.7 (4.6-6.8)
7.6 (4.3-10.8)
12.9 (6.7-19.2)

94.3 (93.2-95.4)
92.4 (89.2-95.7)
87.1 (80.8-93.3)

0.01

4.6 (3.6-5.5)
95.4 (94.5-96.4)

18.0 (11.6-24.4)
5.3 (4.3-6.3)

82.0 (75.6-88.4)
94.7 (93.7-95.7)

<0.01

0.34 (0.20-0.48)
99.7 (99.5-99.8)

23.0 (8.2-37.7)
5.8 (4.8-6.8)

77.0 (62.3-91.8)
94.2 (93.2-95.2)

<0.01

1.7 (1.0-2.3)
98.3 (97.7-99.0)

5.1 (0.60-9.6)
5.9 (4.9-6.9)

94.9 (90.4-99.4)
94.1 (93.1-95.1)

0.71

31.5 (28.4-34.7)
68.5 (65.3-71.6)

7.3 (5.6-9.0)
5.3 (4.3-6.3)

92.7 (91.0-94.4)
94.7 (93.7-95.7)

<0.01

98.7 (98.0-99.4)
1.3 (0.59-2.0)

5.9 (4.9-6.9)
3.6 (0-8.7)

94.1 (93.1-95.1)
96.4 (91.3-100)

0.45

56.9 (55.0-58.8)
30.1 (28.4-31.7)
13.0 (11.4-14.7)

5.8 (4.7-6.9)
6.2 (4.6-7.8)
5.6 (4.0-7.1)

94.2 (93.1-95.3)
93.8 (92.2-95.4)
94.4 (92.9-96.0)

0.74

17.4 (14.7-20.1)
54.7 (51.9-57.6)
27.9 (25.5-30.2)

7.1 (5.2-9.0)
5.8 (4.8-6.8)
5.3 (3.5-7.0)

92.9 (91.0-94.8)
94.2 (93.2-95.2)
94.7 (93.0-96.5)

0.23

Table 2 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TSTtuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core
antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody
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1: Positive LTBI defined by positive QFT-GIT result.
2: Negative LTBI defined by negative QFT-GIT result.
3: All p-values obtained using Rao-Scott chi-square.
4: BMI categories defined according to CDC guidelines[64].
5: Foreign born individuals include those who reported being born in one of the five United States territories.
6: Positive TST defined as an induration >10mm[85].
7: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had diabetes) and according to American Diabetes Association guidelines; participants who self-reported
diabetes were classified as having diabetes regardless of HbA1c.
8: HbA1c categories determined according to American Diabetes Association guidelines[61].
9: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked
at least 100 cigarettes in their lifetime defined as never having smoked[65, 85].
10: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?”
11: Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or
TB?”; specific medicine type not asked.
12: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and
Human Services (HHS) used as poverty measure to calculate ratio of family income to poverty[85].
13: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for
albuminaria categories in chronic kidney disease (CKD)[67].
14: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[85].
15: HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by
response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for
HBsAg[85].
16: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with
repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0
Strip[85].
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17: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had hypertension/high blood pressure)[85].
18: Categories for Total Bilirubin defined according to Medline Plus guidelines[84].
19: Categories for Total Cholesterol defined according to National Institutes of Health guidelines[69].
20: Categories for HDL Cholesterol defined according to Medline Plus guidelines[70].
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Table 3: Multivariable models for odds of latent tuberculosis infection by diabetes status in the civilian,
non-institutionalized United States population aged 20 years and older, 2011-2012
Models
Model 1:
No Diabetes2
Prediabetes
Diabetes
Model 2:
No Diabetes3
Diabetes
Model 3:
No Diabetes
Undiagnosed Diabetes4
Diagnosed Diabetes
Model 4: HbA1c (%)5
<5.7%
5.7-6.4%
≥6.5%
Model 5: HbA1c (%)
<5.7
5.7-6.4
6.5-7.5
7.6-8.5
>8.5

Crude Odds Ratio (95% CI)

Adjusted Odds Ratio (95% CI)1

1.00
1.54 (1.24 – 1.91)
2.70 (1.76 – 4.14)

1.00
1.15 (0.90 – 1.47)
1.90 (1.15 – 3.14)

1.00
2.38 (1.58 – 3.59)

1.00
1.80 (1.14 – 2.83)

1.00
3.06 (1.61 – 5.82)
2.22 (1.46 – 3.38)

1.00
1.96 (1.05 – 3.68)
1.75 (1.09 – 2.80)

1.00
1.71 (1.33 – 2.19)
2.50 (1.64 – 3.81)

1.00
1.30 (0.96 – 1.75)
1.67 (1.04 – 2.69)

1.00
1.71 (1.33 – 2.19)
2.44 (1.48 – 4.01)
3.12 (1.62 – 6.02)
2.21 (1.08 – 4.51)

1.00
1.30 (0.96 – 1.75)
1.66 (0.99 – 2.80)
1.96 (1.06 – 3.63)
1.50 (0.70 – 3.22)

1: Models adjusted for age (categorized as 20-35 years, 35-65 years, and ≥65 years), sex (female, male), smoking
status (current, former, never), history of active TB (yes, no), and foreign born status (yes, no).
2: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who selfreported diabetes were classified as having diabetes regardless of HbA1c.
3: Individuals classified as having prediabetes or no diabetes for Model 1 were classified as not having diabetes for
Model 2.
4: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these
previously undiagnosed participants have no information for duration of diabetes[85].
5: Glycated hemoglobin (HbA1c) categories determined according to American Diabetes Association
guidelines[61].
Bold indicates that the adjusted odds ratio (aOR) is statistically significant
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Table 4: Weighted prevalence of latent tuberculosis (LTBI) infection among only those with diabetes1 in
the civilian, non-institutionalized United States population, adults 20 years and older, 2011-2012
Participant
Characteristics

Age (years)
20 – 34
35 – 64
≥65
Sex
Female
Male
Race/Ethnicity
Hispanic
NH White
NH Black
NH Asian
Foreign Born5
No
Yes
Smoking Status6
Current
Former
Never
Diabetes Duration (years)7
Undiagnosed8
<1
1-3
4-10
≥10
Diabetes Diagnosis Status
Undiagnosed
Diagnosed
Taking insulin
Yes
No
How long taking insulin
(months)9
1-12
13-24
25-36
>36
Oral Agents10
Yes
No
HbA1c (%)11

Totals for
Population
N=793
% (95% CI)

LTBI Positive2
% (95% CI)
11.6
(7.9-15.3)

LTBI Negative3
% (95% CI)
88.4
(84.7-92.1)

p-value4

4.8 (3.2-6.4)
59.9 (55.4-64.6)
35.3 (30.8-39.8)

9.2 (0-21.4)
10.9 (5.5-16.2)
13.1 (9.0-17.3)

90.8 (78.6-100)
89.1 (83.8-94.5)
86.9 (82.7-91.0)

0.71

50.7 (45.6-55.8)
49.3 (44.2-54.4)

11.1 (7.1-15.0)
12.1 (7.6-16.6)

88.9 (85.0-92.9)
87.9 (83.4-92.4)

0.59

17.3 (9.5-25.2)
58.4 (46.3-70.5)
18.3 (10.2-26.3)
6.0 (3.4-8.7)

24.3 (12.4-36.2)
6.9 (3.2-10.6)
11.7 (7.5-15.9)
27.5 (19.0-35.9)

75.7 (63.8-87.6)
93.1 (89.4-96.8)
88.3 (84.1-92.5)
72.5 (64.1-81.0)

<0.01

79.3 (73.3-85.3)
20.7 (14.7-26.7)

6.8 (4.4-9.1)
30.2 (18.8-41.6)

93.2 (90.9-95.6)
69.8 (58.4-81.2)

<0.01

18.0 (14.7-21.3)
32.2 (27.1-37.3)
49.9 (43.7-56.0)

12.5 (7.1-17.8)
14.5 (7.8-21.3)
9.4 (5.1-13.8)

87.5 (82.2-92.9)
85.5 (78.7-92.2)
90.6 (86.2-95.0)

0.21

19.9 (15.3-24.4)
4.8 (2.3-7.2)
16.5 (11.2-21.7)
26.0 (22.7-29.4)
32.9 (26.7-39.0)

14.4 (6.7-22.2)
3.6 (0-8.0)
9.3 (3.1-15.6)
11.1 (6.0-16.3)
12.5 (7.3-17.7)

85.6 (77.8-93.3)
96.4 (92.0-100)
90.7 (84.4-96.9)
88.9 (83.7-94.0)
87.5 (82.3-92.7)

0.32

19.9 (15.3-24.4)
80.1 (75.6-84.7)

14.4 (6.7-22.2)
10.9 (7.4-14.4)

85.6 (77.8-93.3)
89.1 (85.6-92.6)

0.24

23.5 (18.4-28.5)
76.5 (71.5-81.6)

7.3 (3.1-11.4)
12.9 (8.5-17.3)

92.7 (88.6-96.9)
87.1 (82.7-91.5)

0.03

20.9 (13.9-27.9)
11.0 (4.7-17.4)
6.3 (0-13.7)
61.8 (49.1-74.4)

7.2 (0-15.5)
11.0 (0-29.4)
23.0 (3.1-43.0)
4.7 (0.99-8.4)

92.8 (84.5-100)
89.0 (70.6-100)
77.0 (57.0-96.9)
95.3 (91.6-99.0)

0.09

60.4 (55.1-65.6)
39.6 (34.4-44.9)

12.0 (7.5-16.4)
11.0 (6.8-15.2)

88.0 (83.6-92.5)
89.0 (84.8-93.2)

0.65
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<5.7
5.7-6.4
6.5-7.5
7.6-8.5
>8.5
HepB Core Ab12
Positive
Negative
HepC Ab (confirmed)13
Positive
Negative
Self-reported
Hypertension14
Yes
No
Total Cholesterol (mg/dL)15
<200
200-239
≥240
HDL Cholesterol (mg/dL)16
<40
40-59
≥60

5.4 (3.1-7.6)
23.4 (17.1-29.8)
34.8 (28.8-40.7)
14.5 (10.2-18.8)
21.9 (17.7-26.1)

9.1 (2.3-16.0)
14.1 (5.9-22.4)
10.7 (6.2-15.2)
13.3 (5.3-21.3)
9.8 (3.9-15.7)

90.9 (84.0-97.7)
85.9 (77.6-94.1)
89.3 (84.8-93.8)
86.7 (78.7-94.7)
90.2 (84.3-96.1)

0.71

7.8 (5.0-10.7)
92.2 (89.3-95.0)

20.8 (8.9-32.7)
11.0 (7.2-14.9)

79.2 (67.3-91.1)
89.0 (85.1-92.8)

0.04

2.9 (0.80-5.1)
97.1 (94.9-99.2)

3.8 (0-10.4)
12.0 (8.3-15.8)

96.2 (89.6-100)
88.0 (84.2-91.7)

0.06

64.6 (60.8-68.3)
35.4 (31.7-39.2)

10.6 (6.7-14.5)
13.4 (7.4-19.4)

89.4 (85.5-93.3)
86.6 (80.6-92.6)

0.31

64.6 (60.0-69.2)
24.1 (20.2-28.0)
11.3 (7.4-15.1)

10.4 (6.8-13.9)
14.9 (6.9-22.9)
13.4 (1.8-24.9)

89.6 (86.1-93.2)
85.1 (77.1-93.1)
86.6 (75.1-98.2)

0.43

29.6 (21.9-37.2)
57.7 (49.7-65.7)
12.7 (9.1-16.4)

11.9 (6.2-17.6)
11.1 (6.7-15.5)
14.5 (4.3-24.7)

88.1 (82.4-93.8)
88.9 (84.5-93.3)
85.5 (75.3-95.7)

0.75

Table 4 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TSTtuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core
antibody; Anti-HCV-hepatitis C antibody
1: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that
he/she had diabetes) and according to American Diabetes Association guidelines as having an HbA1c (glycated
hemoglobin) level ≥6.5%[61]; participants who self-reported diabetes were classified as having diabetes regardless
of HbA1c.
2: Positive LTBI defined by positive QFT-GIT result.
3: Negative LTBI defined by negative QFT-GIT result.
4: All p-values obtained using Rao-Scott chi-square.
5: Foreign born individuals include those who reported being born in one of the five United States territories.
6: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked
at least 100 cigarettes in their lifetime defined as never having smoked[65, 85].
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7: Refers to how long participant has known they have diabetes; this was calculated using the age of the participant
and his/her response to the survey question regarding how old he/she was when a doctor or other health professional
first told him/her that he/she had diabetes or sugar diabetes[85].
8: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these
previously undiagnosed participants have no information for duration of diabetes[85].
9: Among participants who answered “yes” to taking insulin.
10: Determined by response to survey question “Are you now taking diabetic pills to lower your blood sugar?”;
specific medications not determined[85].
11: HbA1c categories determined according to American Diabetes Association guidelines[61].
12: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[85].
13: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with
repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0
Strip[85].
14: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had hypertension/high blood pressure)[85].
15: Categories for Total Cholesterol defined according to National Institute of Health guidelines[69].
16: Categories for HDL Cholesterol defined according to Medline Plus guidelines[70].
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Supplemental Table 1: Multivariable models for odds of latent tuberculosis infection associated with
diabetes status in the civilian, non-institutionalized United States population aged 20 years and older,
2011-2012:
Models
Model 1
No Diabetes2
Prediabetes
Diabetes
Model 2
No Diabetes
Prediabetes
Diabetes
Model 3
No Diabetes
Prediabetes
Diabetes
Model 4
No Diabetes
Prediabetes
Diabetes
Model 5
No Diabetes
Prediabetes
Diabetes
Model 6
No Diabetes
Prediabetes
Diabetes
Model 7
No Diabetes
Prediabetes
Diabetes
Model 8
No Diabetes
Prediabetes
Diabetes
Model 9
No Diabetes
Prediabetes
Diabetes
Model 10
No Diabetes
Prediabetes
Diabetes

Covariates1

Adjusted Odds Ratio
(95% CI)
1.00
0.95 (0.75 – 1.21)
1.49 (0.83 – 2.68)
1.00
1.21 (0.90 – 1.62)
2.04 (1.17 – 3.57)
1.00
1.06 (0.81 – 1.35)
1.49 (0.84 – 2.64)
1.00
1.05 (0.82 – 1.35)
1.55 (0.91 – 2.65)
1.00
1.25 (0.93 – 1.68)
2.20 (1.22 – 3.96)
1.00
1.07 (0.83 – 1.37)
1.67 (1.01 – 2.74)
1.00
1.09 (0.79 – 1.41)
1.61 (0.86 – 2.99)
1.00
1.17 (0.92 – 1.49)
1.93 (1.17 – 3.21)

age, sex, education, previous history of active TB,
ethnicity, income to poverty ratio, ACR, HepB surface
antigen, HepB core antibody, smoking status, foreign
born status, and hypertension
age, sex, ACR, HepB surface antigen, and HepB core
antibody

age, sex, education, ethnicity, and income to poverty
ratio

age, sex, ethnicity, country of birth, income to poverty
ratio, smoking status, and education

age, sex, BMI, ACR, HepB surface antigen, HepB
core antibody and hypertension

age, sex, smoking status, ethnicity, and country of
birth

age, sex, BMI, hypertension, ethnicity, and income to
poverty ratio

age, sex, country of birth, previous history of active
TB, and smoking status

age, sex, BMI, education, and income to poverty ratio
1.00
1.22 (0.93 – 1.60)
1.86 (1.00 – 3.46)
age, sex, ethnicity, BMI, and country of birth
1.00
1.12 (0.84 – 1.49)
1.76 (1.02 – 3.03)

Supplemental Table 1 Abbreviations: TB-tuberculosis; ACR-albumin-creatinine ratio
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1: Covariates controlled for in multivariable logistic model.
2: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional
that he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who selfreported diabetes were classified as having diabetes regardless of HbA1c.
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Figure 1: Flow chart showing process of selection for NHANES 2011-2012 participants eligible for study,
including the categorization of eligible participants by diabetes status; raw numbers and percentages not
weighted for NHANES sampling methodology.
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